01—Abstract
Summary
Summary of the 10-K filed February 9, 2024. Cited figures are marked; the original filing is the authoritative source.
Mettler-Toledo International Inc. reported net sales of $3.79 billiona for 2023, down from $3.92 billion in 2022, a decrease of 3% in both U.S. dollars and local currencies.
The company attributed the decline to reduced market demand, particularly in China and its laboratory business, and to shipping delays of approximately $58 millionb with a new external European logistics provider, which it expects to largely recover in the first quarter of 2024. Net earnings fell to $788.8 million ($35.90 diluted earnings per share) from $872.5 million ($38.41 in 2022). Gross margin improved to 59.2% of net sales from 58.9%, reflecting favorable price realization and cost savings, partly offset by lower volume, unfavorable mix, and currency.
Chinese Operations was the weakest segment, with net sales down 13% in U.S. dollars and segment profit down $57.1 millionc, as China's market demand declined significantly in the second half of 2023. U.S. Operations segment profit rose to $365.1 million, and Western European Operations and Other segments also improved profit. Product sales declined 7%, while service revenue grew 10% in both U.S. dollars and local currencies, and service represented 23% of net sales in 2023.
Cash flow remained solid, with operating cash flow of $965.9 milliond. The company repurchased $900.0 million of its stock during 2023, leaving $2.6 billion of authorization remaining, and it expects to spend approximately $850.0 million on repurchases in 2024.
Total debt was $2.08 billion against cash of $69.8 million, and shareholders' equity was negative $149.9 million. Management expects reduced demand in the first half of 2024, especially in laboratory and China-related businesses.
02—Key points
Key Highlights
- Net sales were $3.79 billion in 2023, down 3% from $3.92 billion in 2022, with laboratory products (55% of sales) down 7% and industrial products (39% of sales) down 1%.
- Net earnings were $788.8 million, or $35.90 per diluted share, compared with $872.5 million, or $38.41 per diluted share, in 2022.
- Chinese Operations net sales fell 13% in U.S. dollars and segment profit fell $57.1 million, as Chinese market demand declined significantly in the second half of 2023.
- Gross profit as a percentage of net sales improved to 59.2% from 58.9%, driven by favorable price realization and cost savings initiatives.
- Operating cash flow was $965.9 million, and the company repurchased $900.0 million of common stock, with $2.6 billion of authorization remaining at year end.
- Total debt was $2.08 billion at December 31, 2023, and the company was in compliance with its debt covenants; the company expects to spend approximately $850.0 million on share repurchases in 2024.
- Management expects reduced demand in the first half of 2024, particularly in its laboratory business and in China, after strong results in 2023 and 2022.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 9, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $3.79B$3.92B | −3.4% |
| Gross Profit | $2.24B$2.31B | −2.9% |
| R&D Expenses | $185.28M$177.12M | +4.6% |
| SG&A Expenses | $904.11M$938.46M | −3.7% |
| Interest Expense | $77.37M$55.39M | +39.7% |
| Net Income | $788.78M$872.50M | −9.6% |
| EPS (Basic) | $36.10$38.79 | −6.9% |
| EPS (Diluted) | $35.90$38.41 | −6.5% |
| Shares Outstanding (Basic) | 21.85M22.49M | −2.9% |
| Shares Outstanding (Diluted) | 21.97M22.72M | −3.3% |
05—Questions
Frequently Asked Questions
Why did Mettler-Toledo's sales decline in 2023?
Net sales decreased 3% in both U.S. dollars and local currencies, to $3.79 billion. The filing cites reduced market demand, particularly in China and in the laboratory business after two years of strong growth, along with shipping delays of approximately $58 million with a new external European logistics provider, which the company expects to largely recover in the first quarter of 2024.
How did the China business perform?
Chinese Operations net sales decreased 13% in U.S. dollars to $996.8 million, and segment profit decreased $57.1 million to $367.1 million. Local currency net sales to external customers fell 11%, reflecting a significant decline in market demand during the second half of 2023. The company expects China net sales to decrease again in the first half of 2024.
Does the company pay dividends, and how is it returning capital to shareholders?
Historically, the company has not paid dividends on its common stock, though it will evaluate this policy periodically. It returns capital through share repurchases: it spent $900.0 million on repurchases in 2023 and intends to spend approximately $850.0 million in 2024, with $2.6 billion of authorization remaining at December 31, 2023.
How is the company's debt and liquidity position?
Total debt was $2.08 billion at December 31, 2023, against cash and cash equivalents of $69.8 million. The company had approximately $606.4 million of additional borrowings available under its $1.25 billion Credit Agreement, and 78% of its debt carried fixed interest obligations. Management believes cash flows from operations and available liquidity will be sufficient for its anticipated needs.
What is the outlook for 2024?
The company expects to continue benefiting from automation, digitalization, and onshoring trends, but expects reduced demand during the first half of 2024, reflecting difficult prior-period comparisons, particularly in its laboratory business and in China. Capital expenditures in 2024 are expected to be relatively consistent with 2023, subject to business and economic conditions.
06—Continue